论文部分内容阅读
山西太龙生化实业有限公司是集科研、生产、营销一体化的现代化公司,公司拥有自己的生物科研机构——太原维尔新生物研究所。医学界认为,心脑血管病的死亡率占疾病总死亡率40%以上,是人类“第一杀手”。如何有效地防治心脑血管病成了国内外医学界的一个重大研究课题。此前治疗心脑血管病停留在扩张血管、改善供血、稀释血液、防止栓塞的水平上,不能从根本上解除病情。既然心脑血管疾病的病根是动脉硬化,那么治疗的关键就是阻
Shanxi Tailong Biochemical Industry Co., Ltd. is a modernized company integrating scientific research, production and marketing. The company has its own biological research institute—Taiyuanville New Biological Research Institute. The medical community believes that the mortality of cardiovascular and cerebrovascular diseases accounts for more than 40% of the total mortality of the disease and is the “first killer” of humans. How to effectively prevent cardiovascular and cerebrovascular diseases has become a major research topic in the medical community at home and abroad. Previous treatment of cardiovascular and cerebrovascular diseases stayed at the level of dilating blood vessels, improving blood supply, diluting blood, and preventing embolism, and could not be fundamentally relieved. Since the root cause of cardiovascular disease is atherosclerosis, the key to treatment is resistance.